Complexity in the US healthcare system is not new, and neither is the debate over the rising cost of care. From a payer standpoint, drug prices remain a central focus. What has changed is the tone: Pharmacy directors are increasingly discussing cross-channel price disparities not as background noise, but as leverage points in the ongoing effort to control drug spend.
This white paper examines how rising price transparency is reshaping payer negotiation strategy. In a market where payers can essentially 'know the price of everything,' are they beginning to see the value of nothing, focusing solely on the lowest net cost rather than on differentiated value?
The paper provides a framework for understanding when public prices move contracts and four concrete actions manufacturers should take to protect profitability in this transparent environment.